ZyVersa Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ZyVersa Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.95M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.41M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($98.30M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($75.0K) | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | ($14.05M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | ($240.7K) | Apr 15, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.49M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.14M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($107.75M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($820.1K) | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | ($13.01M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | ($235.3K) | Apr 15, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.78M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.21M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $399.9K | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | $5.41M | Mar 25, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.11M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.52M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.72M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($3.39M) | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | ($1.49M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | ($428.8K) | Apr 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.11M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $118.51M | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | $77.14M | Apr 15, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.04M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $18.51M | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | $3.65M | Apr 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.39M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $11.07M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $99.66M | Mar 27, 2025 |
| FY2023 | Dec 12, 2022 | $99.68M | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | ($2.26M) | Apr 15, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $11.90M | Mar 25, 2024 |
| FY2023 | Dec 31, 2022 | $11.90M | Mar 25, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($137.58M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($112.63M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($103.22M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($4.92M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | ($2.26M) | Apr 15, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $928.4K | Apr 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1,089) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | 0 | Mar 25, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1,089) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2023 | Dec 12, 2022 | 0 | Mar 25, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.51M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 402,205 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 257,604 | Mar 25, 2024 |